| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
36,651,000 |
| Market
Cap: |
570.29(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$11.84 - $28.66 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Quanterix is a life sciences company that has developed digital immunoassay platforms. Co.'s platforms are based on its proprietary digital Simoa detection technology. Co. provides the following three Simoa instruments: HD-X, which is based on Co.'s bead-based technology, and assays run on the HD-X are fully automated; SR-X, which utilizes the same Simoa bead-based technology and assay kits as the HD-X in a compact benchtop form with a range of applications; and SP-X, which is based on Co.'s planar array technology, which allows for multiplexing capabilities for oncology and immunology applications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
20,200 |
639,331 |
| Total Buy Value |
$0 |
$0 |
$501,978 |
$6,053,841 |
| Total People Bought |
0 |
0 |
1 |
7 |
| Total Buy Transactions |
0 |
0 |
1 |
8 |
| Total Shares Sold |
2,500 |
5,000 |
5,000 |
10,265 |
| Total Sell Value |
$60,025 |
$119,770 |
$119,770 |
$214,084 |
| Total People Sold |
1 |
1 |
1 |
5 |
| Total Sell Transactions |
2 |
4 |
4 |
15 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hrusovsky E Kevin |
Chairman and CEO |
• • – |
2021-10-22 |
4 |
AS |
$50.19 |
$253,520 |
D/D |
(5,000) |
906,316 |
|
-45% |
|
| Duffy David C. |
SVP R&D and CTO |
• – – |
2021-10-15 |
4 |
AS |
$51.47 |
$85,800 |
D/D |
(1,667) |
26,616 |
|
-35% |
|
| Fry John J |
General Counsel & Secretary |
• – – |
2021-10-01 |
4 |
S |
$51.20 |
$17,408 |
D/D |
(340) |
33,009 |
|
35% |
|
| Roskey Mark T. |
SVP, Strategic Partnerships |
• – – |
2021-10-01 |
4 |
S |
$51.20 |
$7,322 |
D/D |
(143) |
23,555 |
|
35% |
|
| Mcconnell Sarah H |
|
– • – |
2021-10-01 |
4 |
A |
$51.18 |
$11,874 |
D/D |
232 |
11,892 |
|
- |
|
| Mattoon Dawn |
Sr. VP, Diagnostics |
• – – |
2021-10-01 |
4 |
S |
$51.20 |
$17,511 |
D/D |
(342) |
36,848 |
|
35% |
|
| Meister Paul M |
|
– • – |
2021-10-01 |
4 |
A |
$51.18 |
$13,767 |
D/D |
269 |
13,930 |
|
- |
|
| Madaus Martin D |
|
– • – |
2021-10-01 |
4 |
A |
$51.18 |
$18,118 |
D/D |
354 |
15,348 |
|
- |
|
| Crandell Keith |
|
– • • |
2021-10-01 |
4 |
A |
$51.18 |
$13,000 |
D/D |
254 |
96,012 |
|
- |
|
| Hrusovsky E Kevin |
Chairman and CEO |
• • – |
2021-10-01 |
4 |
AS |
$51.20 |
$184,015 |
D/D |
(3,594) |
911,316 |
|
-35% |
|
| Hrusovsky E Kevin |
Chairman and CEO |
• • – |
2021-09-30 |
4 |
AS |
$47.54 |
$245,449 |
D/D |
(5,000) |
914,910 |
|
-32% |
|
| Duffy David C. |
SVP R&D and CTO |
• – – |
2021-09-22 |
4 |
AS |
$47.72 |
$79,549 |
D/D |
(1,667) |
28,283 |
|
-35% |
|
| Hrusovsky E Kevin |
Chairman, President & CEO |
• • – |
2021-09-02 |
4 |
AS |
$49.66 |
$248,307 |
D/D |
(5,000) |
919,910 |
|
-36% |
|
| Roskey Mark T. |
SVP, Strategic Partnerships |
• – – |
2021-09-01 |
4 |
S |
$49.78 |
$7,338 |
D/D |
(147) |
23,698 |
|
34% |
|
| Mattoon Dawn |
Sr. VP, Diagnostics |
• – – |
2021-09-01 |
4 |
S |
$49.78 |
$17,622 |
D/D |
(353) |
37,190 |
|
34% |
|
| Fry John J |
General Counsel & Secretary |
• – – |
2021-09-01 |
4 |
S |
$49.78 |
$17,472 |
D/D |
(350) |
33,349 |
|
34% |
|
| Hrusovsky E Kevin |
Chairman, President & CEO |
• • – |
2021-09-01 |
4 |
AS |
$49.78 |
$185,158 |
D/D |
(3,709) |
924,910 |
|
-34% |
|
| Duffy David C. |
SVP R&D and CTO |
• – – |
2021-08-20 |
4 |
AS |
$46.13 |
$76,899 |
D/D |
(1,667) |
29,950 |
|
-12% |
|
| Crandell Keith |
|
– • • |
2021-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
9,954 |
95,758 |
|
- |
|
| Crandell Keith |
|
– • • |
2021-08-17 |
4 |
D |
$0.00 |
$0 |
I/I |
(310,000) |
233,692 |
|
- |
|
| Hrusovsky E Kevin |
Chairman, President & CEO |
• • – |
2021-08-16 |
4 |
AS |
$47.20 |
$236,669 |
D/D |
(5,000) |
928,619 |
|
-10% |
|
| Crandell Keith |
|
– • • |
2021-08-10 |
4 |
A |
$0.00 |
$0 |
D/D |
9,952 |
85,804 |
|
- |
|
| Crandell Keith |
|
– • • |
2021-08-10 |
4 |
D |
$0.00 |
$0 |
I/I |
(310,000) |
354,381 |
|
- |
|
| Fry John J |
General Counsel & Secretary |
• – – |
2021-08-03 |
4 |
S |
$53.79 |
$18,503 |
D/D |
(344) |
33,699 |
|
26% |
|
| Roskey Mark T. |
SVP, Strategic Partnerships |
• – – |
2021-08-03 |
4 |
S |
$53.79 |
$7,799 |
D/D |
(145) |
23,845 |
|
26% |
|
278 Records found
|
|
Page 4 of 12 |
|
|
0.03 (0.19%) 
